

PAOLO GISONDI

CURRICULUM VITAE

Personal

Name: Paolo Gisondi

Nationality: Italian

Date of birth: 19/04/1972 in Rome

Family details: married and father of one child.

Address: Via G. Carducci CAP 37026 Pescantina (Verona). ITALY

Contact: office 00 39 0458122546.

E-mail: paolo.gisondi@univr.it

Qualification

Specialisation in Dermatology and Venereology at the University of Parma in November 2002.

Medical license released in Rome on 14 September 1998 number M 48735

Degree in Medicine and Surgery at the Catholic University of Sacred Heart-Rome in October 1997.

Employment

Since January 2018 Director of the school of specialization in Dermatology and Venereology University of Verona, Italy.

Since December 2014 associate professor of Dermatology at the Department of Medicine, Section of Dermatology and Venereology University of Verona, Italy.

From 2006 to 2014, researcher assistant at the Department of Medicine, Section of Dermatology and Venereology University of Verona, Italy. Before moving to Verona, I worked for two years at the Istituto Dermopatico dell'Immacolata of Rome.

Scientific interest

Dr P. Gisondi began his scientific activity at the Dermopathic Institute of the Immacolata where he was actively interested in clinical dermatology through the conception and participation in epidemiological studies, and studies on the quality of life in psoriasis, psoriatic arthritis, atopic dermatitis and patients with oral cavity pathology. In the same period he participated as a sub-investigator in some clinical research protocols mainly concerning biological drugs in the treatment

of psoriasis and topical calcineurin inhibitors in atopic dermatitis. Since June 2005, Dr P. Gisondi has been interested in the design and implementation of epidemiological studies to evaluate the association between psoriasis and its metabolic and cardiovascular comorbidities. In particular, his research focuses on the association between psoriasis and metabolic syndrome, hepatic steatosis and cardiovascular risk biomarkers including homocysteine, vitamin D and adipokines. He performed a study to estimate cardiovascular risk in psoriatic patients using the Framingham algorithm and evaluated the state of stiffness of the carotid arterial vessels. Another field of interest is pharmacological treatments with traditional and biological drugs. He participated as a co-author in the drafting of the European guidelines on the treatment of psoriasis and in the definition of the therapeutic outcomes of moderate-severe psoriasis. He verified the patients' adherence to the various treatments over time and the reasons for their suspension. He studied possible therapeutic associations between anti-TNF-alpha drugs and acitretin and evaluated the effect of systemic treatments on metabolic parameters, including body weight, C-reactive protein and adipokines. Furthermore, he verified the beneficial effect of a low-calorie diet in obese patients with moderate-severe psoriasis. Another area of interest is psoriatic arthropathy. He estimated its prevalence in patients with psoriasis. He was interested in identifying instrumental parameters that can help in the diagnosis of psoriatic arthritis in the early stage, such as a specific questionnaire dedicated to patients with psoriasis. He measured the thickness of the tendons as a possible marker of risk of arthropathy. He identified the thickness of the nail plate as a possible diagnostic marker of psoriasis.

Clinical activity

Dr P. Gisondi began his clinical-assistance activity at the Catholic University of the Sacred Heart of Rome where he graduated in Medicine and Surgery in 1997 and obtained the qualification to practice the profession of Medical Surgeon in 1998. Subsequently, he worked as a visiting doctor from October 1997 to May 1998 at the San Gallicano Dermatological Institute-IRCCS in Rome, and from June 1998 to October 1998 at the Dermopathic Institute of the Immacolata-IRCCS collaborating with the structured staff to assist patients. In the years 1998-2002 he obtained a specialization in Dermatology and Venereology at the Dermatology Clinic of the University of Parma. From December 2002 to June 2005 he worked at the Dermopathic Institute of the Immacolata-IRCCS carrying out clinical-assistance activities both at the II and VI Dermatological Divisions and at the institutional outpatient clinics. In recent years he has participated as an investigator in some sponsored clinical trials on biological drugs for the treatment of psoriasis. Since July 2005 he has been responsible for the psoriasis clinic at the Dermatology Clinic of the University of Verona where approximately 2000 patients with moderate-severe psoriasis and/or psoriatic arthritis are currently being followed. He

established a joint clinic with colleagues from Rheumatology to follow patients suffering from psoriatic arthritis and rheumatic patients with skin manifestations in a coordinated manner. He carried out clinical-assistance activities in a joint dermato-allergology clinic together with colleagues in the Allergy Division, where he mainly follows adult patients with atopic dermatitis or urticaria. He carried out clinical-assistance activities in a joint clinic together with colleagues in maxillofacial surgery for oral cavity pathologies. Since January 2009 he has worked at the surgical dermatology clinic, where he performs skin biopsies and ordinary dermatological surgery. He is a consultant for the departments of Rheumatology, Endocrinology, Gastroenterology, Neurosurgery, Pneumology and Anesthesia and Intensive care unit.

Member of the scientific societies

Member of the European Academy of Dermatology and Venereology

Executive commette member of the Società Italiana di Dermatologia medica, chirurgia, estetica e delle malattie sessualmente trasmesse

Member of group of study of psoriasis and psoriatic arthritis (GRAPPA)

Member of the International Psoriasis Council

PUBLICATIONS IN SCIENTIFIC JOURNALS IN 2023

1. Duffin KC, Mazzuocolo LD, Cura MJ, Esposito M, Fernandez AP, Gisondi P, Giunta A, Hillary T, Piaserico S, Solomon JA, Merola JF. Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. *J Rheumatol.* 2023 Jan;50(1):131-143. doi: 10.3899/jrheum.220316. Epub 2022 Nov 1. PMID: 36319014.
2. Gisondi P, Maurelli M, Costanzo A, Esposito M, Girolomoni G. The Combination of Dupilumab with Other Monoclonal Antibodies. *Dermatol Ther (Heidelb).* 2023 Jan;13(1):7-12. doi: 10.1007/s13555-022-00851-6. Epub 2022 Nov 10. PMID: 36355314; PMCID: PMC9823163.
3. Bellinato F, Chiricozzi A, Piaserico S, Targher G, Gisondi P. Could Targeted Pharmacotherapies Exert a "Disease Modification Effect" in Patients with Chronic Plaque Psoriasis? *Int J Mol Sci.* 2022 Oct 25;23(21):12849. doi: 10.3390/ijms232112849. PMID: 36361639; PMCID: PMC9658165.
4. Maurelli M, Colato C, Gisondi P, Girolomoni G. Uncommon Non-Infectious Annular Dermatoses. *Indian J Dermatol.* 2022 May-Jun;67(3):313. doi: 10.4103/ijd.ijd_743_21. PMID: 36386081; PMCID: PMC9644792.

5. Bellinato F, Gisondi P, Filippucci E, Tozzi F, Fassio A, Adami G, Idolazzi L. Correction to: Systematic study on nail plate assessment: differences in nail plate shape, thickness, power Doppler signal and scanning approach. *Arch Dermatol Res.* 2022 Nov 25. doi: 10.1007/s00403-022-02474-5. Epub ahead of print. Erratum for: *Arch Dermatol Res.* 2022 Oct 21;; PMID: 36434322.
6. Bonetti G, Medori MC, Fioretti F, Farronato M, Nodari S, Lorusso L, Tartaglia GM, Farronato G, Bellinato F, Gisondi P, Connelly ST, Bertelli M. Dietary supplements for the management of COVID-19 symptoms. *J Prev Med Hyg.* 2022 Oct 17;63(2 Suppl 3):E221-E227. doi: 10.15167/2421-4248/jpmh2022.63.2S3.2764. PMID: 36479480; PMCID: PMC9710408.
7. Kiani AK, Bonetti G, Donato K, Kaftalli J, Herbst KL, Stuppia L, Fioretti F, Nodari S, Perrone M, Chiurazzi P, Bellinato F, Gisondi P, Bertelli M. Polymorphisms, diet and nutrigenomics. *J Prev Med Hyg.* 2022 Oct 17;63(2 Suppl 3):E125-E141. doi: 10.15167/2421-4248/jpmh2022.63.2S3.2754. PMID: 36479483; PMCID: PMC9710387.
8. Naureen Z, Medori MC, Dhuli K, Donato K, Connelly ST, Bellinato F, Gisondi P, Bertelli M. Polyphenols and *Lactobacillus reuteri* in oral health. *J Prev Med Hyg.* 2022 Oct 17;63(2 Suppl 3):E246-E254. doi: 10.15167/2421-4248/jpmh2022.63.2S3.2767. PMID: 36479495; PMCID: PMC9710395.
9. Dhuli K, Bonetti G, Anpilogov K, Herbst KL, Connelly ST, Bellinato F, Gisondi P, Bertelli M. Validating methods for testing natural molecules on molecular pathways of interest in silico and in vitro. *J Prev Med Hyg.* 2022 Oct 17;63(2 Suppl 3):E279-E288. doi: 10.15167/2421-4248/jpmh2022.63.2S3.2770. PMID: 36479497; PMCID: PMC9710400.
10. Kiani AK, Dhuli K, Donato K, Aquilanti B, Velluti V, Matera G, Iaconelli A, Connelly ST, Bellinato F, Gisondi P, Bertelli M. Main nutritional deficiencies. *J Prev Med Hyg.* 2022 Oct 17;63(2 Suppl 3):E93-E101. doi: 10.15167/2421-4248/jpmh2022.63.2S3.2752. PMID: 36479498; PMCID: PMC9710417.
11. Bonetti G, Herbst KL, Dhuli K, Kiani AK, Michelini S, Michelini S, Ceccarini MR, Michelini S, Ricci M, Cestari M, Codini M, Beccari T, Bellinato F, Gisondi P, Bertelli M. Dietary supplements for lipedema. *J Prev Med Hyg.* 2022 Oct 17;63(2 Suppl 3):E169-E173. doi: 10.15167/2421-4248/jpmh2022.63.2S3.2758. PMID: 36479502; PMCID: PMC9710418.
12. Gisondi P, Gottlieb AB, Elewski B, Augustin M, McBride S, Tsai TF, de la Loge C, Fierens F, López Pinto JM, Tilt N, Lebwohl M. Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2). *Dermatol Ther (Heidelb).* 2023 Jan;13(1):315-

328. doi: 10.1007/s13555-022-00861-4. Epub 2022 Dec 13. PMID: 36509889; PMCID: PMC9823190.
13. Chiricozzi A, Bellinato F, Romita P, Gisondi P. Psoriasis: talking points from recent clinical trials. *Expert Opin Investig Drugs*. 2022 Dec;31(12):1265-1267. doi: 10.1080/13543784.2022.2160314. Epub 2022 Dec 25. PMID: 36526606.
 14. Gisondi P, Simon D, Alarcon I, Pournara E, Puig L. Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review. *J Dermatolog Treat*. 2023 Dec;34(1):2167487. doi: 10.1080/09546634.2023.2167487. PMID: 36625506.
 15. Mareso C, Albion E, Cozza W, Tanzi B, Cecchin S, Gisondi P, Michelini S, Bellinato F, Michelini S, Bertelli M, Marceddu G. Optimization of long-range PCR protocol to prepare filaggrin exon 3 libraries for PacBio long-read sequencing. *Mol Biol Rep*. 2023 Jan 24. doi: 10.1007/s11033-022-08170-x. Epub ahead of print. PMID: 36692677.
 16. Quirke-McFarlane S, Weinman J, Cook ES, Yiu ZZN, Dand N, Langan SM, Bechman K, Tsakok T, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Barbosa IA, Bachelez H, Capon F, Contreras CR, De La Cruz C, Di Meglio P, Gisondi P, Jullien D, Lambert J, Naldi L, Puig L, Spuls P, Torres T, Warren RB, Waweru H, Galloway JB, Griffiths CEM, Barker JN, Norton S, Smith CH, Mahil SK; PsoProtect study group. Non-adherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey. *Br J Dermatol*. 2022 Dec 23;ljac144. doi: 10.1093/bjd/ljac144. Epub ahead of print. PMID: 36763806.
 17. Bellinato F, Gisondi P, Marzano AV, Piaserico S, De Simone C, Damiani G, Argenziano G, Venturini M, Dapavo P, Costanzo A, Megna M, Prignano F, Burlando M, Satolli F, Carugno A, Pezzolo E, Romanelli M, Cuccia A, Girolomoni G. Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study. *Vaccines (Basel)*. 2023 Mar 27;11(4):740. doi: 10.3390/vaccines11040740. PMID: 37112652; PMCID: PMC10143954.
 18. Talamonti M, Russo F, Malara G, Hansel K, Papini M, Cattaneo A, Parodi A, Chiricozzi A, Malagoli P, Bardazzi F, Brazzelli V, Dapavo P, Gisondi P, Zane C, Potenza C, Cantoresi F, Fagnoli MC, Trevisini S, Brianti P, Pescitelli L, Gigante G, Bartezaghi M, Caputo L, Aloisi E, Costanzo A; SUPREME Study Group. Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study. *Clin Cosmet Investig Dermatol*. 2023 Apr 1;16:847-852. doi: 10.2147/CCID.S400520. PMID: 37033782; PMCID: PMC10075320.

19. Gisondi P, Geat D, Colato C, Girolomoni G. Recurrent cutaneous eosinophilic vasculitis characterized by annular purpuric lesions: A case report. *SAGE Open Med Case Rep.* 2023 Mar 28;11:2050313X231163636. doi: 10.1177/2050313X231163636. PMID: 37009553; PMCID: PMC10052476.
20. Maurelli M, Gisondi P, Girolomoni G. Advanced Glycation End Products and Psoriasis. *Vaccines (Basel).* 2023 Mar 8;11(3):617. doi: 10.3390/vaccines11030617. PMID: 36992201; PMCID: PMC10056603.
21. Bellinato F, Gisondi P, Fassio A, Girolomoni G. Central Pain Sensitization in Patients with Chronic Plaque Psoriasis. *Dermatol Ther (Heidelb).* 2023 May;13(5):1149-1156. doi: 10.1007/s13555-023-00917-z. Epub 2023 Mar 29. PMID: 36988902.
22. Gnesotto L, Mioso G, Bardazzi F, Filippi F, Di Lernia V, Motolese A, Di Nuzzo S, Conti A, Arginelli F, Corazza M, Odorici G, Borghi A, Gisondi P, Naldi L, Dapavo P, Parodi A, Burlando M, Piaserico S. Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study. *Acta Derm Venereol.* 2023 Mar 28;103:adv4526. doi: 10.2340/actadv.v103.4526. PMID: 36987538; PMCID: PMC10077142.
23. Bellinato F, Adami G, Furci A, Cattani G, Schena D, Girolomoni G, Gisondi P. Association between short-term exposure to environmental air pollution and atopic dermatitis flare in patients treated with dupilumab. *JAAD Int.* 2023 Feb 10;11:72-77. doi: 10.1016/j.jdin.2023.01.018. PMID: 36937029; PMCID: PMC10020116.
24. Cortesi PA, Fornari C, Gisondi P, Iannone F, Antonazzo IC, Aloisi E, Fiocchi M, Ritrovato D, Mantovani LG. A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy. *Pharmacoecon Open.* 2023 Mar 16. doi: 10.1007/s41669-023-00404-3. Epub ahead of print. PMID: 36929647.
25. Maurelli M, Colato C, Gisondi P, Girolomoni G. Eosinophilic annular erythema successfully treated with cyclosporine. *Ital J Dermatol Venerol.* 2023 Mar 7. doi: 10.23736/S2784-8671.23.07431-5. Epub ahead of print. PMID: 36881333.

CHAPTERS IN SCIENTIFIC BOOKS

1. Girolomoni G, Gisondi P, Zambruno G. L'organo pelle: struttura, biologia, funzioni. In: *Dermatologia basata sulle prove di efficacia*. Naldi L, Rebora A, Liberati A, Eds Masson, 2005 (Milano)

2. Girolomoni G, Gubinelli E, Gisondi P. Dermite atopica. In: *Dermatologia basata sulle prove di efficacia*. Naldi L, Rebora A, Liberati A, Eds Masson, 2005 (Milano)
3. Gisondi P, De Pità O, Cantini S, Girolomoni G. *Psoriasi. Una guida per una migliore gestione del paziente*. E.L.I. service, Villaricca (Napoli), 2004.
4. Gisondi P, Girolomoni G. Casi clinici etanercept e terapia di induzione. Elsevier 2006 Milano.
5. Allegra F, Gisondi P. Le malattie della mucosa orale. In: *Trattato di dermatologia*. Giannetti A. Piccin Nuova Libreria, 2006.
6. Gisondi P Girolomoni G. Psoriasi a placche diffusa in un paziente diabetico a elevato rischio cardiovascolare. In: *Etanercept e terapia d'induzione*. Elsevier Italia Srl, Milano, 2006.
7. Gisondi P Girolomoni G. Psoriasi a placche diffusa in una paziente intollerante alle terapie convenzionali e resistente alla terapia con infliximab: successo di etanercept. In: *Etanercept e terapia d'induzione*. Elsevier Italia Srl, Milano, 2006.
8. Gisondi P. Psoriasi e comorbidità metaboliche. *Quaderma* anno 1- Numero 2 di Qua.derma- Ottobre/Novembre/Dicembre 2007.
9. Girolomoni G, Gisondi P, Boner A. Eziopatogenesi della dermatite atopica. In: La dermatite atopica: dalla teoria alla pratica. In Gelmetti C, Ed. *La pratica della atopia*. Spingler-Verlag Italia, Milano. Pag. 81-86, 2008.
10. Del Giglio M, Gisondi P, Girolomoni G. La dermatite atopica nella seconda infanzia ed adolescenza. In: *Dermatologia Pediatrica e dell'adolescenza*. Lotti T, Greco A, De Martino M, Eds C.I.C.-Edizioni Internazionali, Roma 2009, pagina 215-229.
11. Del Giglio M, Gisondi P, Girolomoni G. Complicanze dermatologiche del bambino obeso 2008. *Le patologie endocrine del bambino*. 2009
12. Gisondi P, Girolomoni G. The metabolic syndrome in psoriasis. In: Clinical and Pathological Aspects of Skin Diseases in Endocrine, Metabolic, Nutritional and Deposition Diseases. Franco Rongioletti and Bruce R Smoller, (Eds.) 2010, Springer Science+Business Media, LLC 2010.
13. Gestione del rischio infettivologico nei pazienti psoriasica. Approfondimenti su tubercolosi ed epatite. Elsevier Srl. 2010 Milano, Italia
14. Psoriasi e comorbidità cardio-metaboliche. Aspetti clinici e implicazioni terapeutiche. Elsevier Srl. 2010 Milano, Italia
15. Gestione terapeutica del paziente psoriasica. Switch e associazioni farmacologiche. Elsevier Srl. 2010 Milano, Italia
16. Management del paziente psoriasico in età geriatrica. Elsevier Srl. 2011 Milano, Italia.
17. Management del paziente psoriasico e aderenza terapeutica. Elsevier Srl. 2012 Milano, Italia.

18. I volumi di clinical practice. Approccio terapeutico in situazioni particolari o controverse. Derma Day Sharing Practices. Effetti srl Milano, Italia, 2011.
19. Vitamina D in Dermatologia. ADIPSO, organo della associazione ADIPSO 2015.
20. Assessing the impact of psoriasis on quality of life and the burden of disease. Educational handbook of biologics in psoriasis. Andrea Porter 2015. Novartis.
21. Review and Commentary to two papers (Association with Genetic Variants in the IL-23 and NF- κ B Pathways Discriminates between Mild and Severe Psoriasis Skin Disease; Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial) for IPC Psoriasis Review newsletter 2016.
22. PEARLS Psoriasis Summary Handbook chapter 3 on psoriasis and associated conditions 2016.
23. La terapia con farmaci biologici in Dermatologia. In “Dermatologia Medica e Chirurgica“ di Giannetti, Cainelli Mc Grow Hill. Milano 2016.
24. L’artrite psoriasica dal punto di vista del dermatologo. ARS Reumatologica. Editore Edizioni Internazionali EDIMES-Pavia 2015;3:26-32.
25. Diabetes and skin in “Endocrinology: Diabetes Complications, Comorbidities and Related Disorders” by Enzo Bonora, Ralph DeFronzo. Springer 2018.

4.3 ABSTRACTS IN SCIENTIFIC CONGRESSES IN 2023-2024

1. L. Puig, P. Gisondi, A. Pinter, Christine de la Loge, J.M. López Pinto, I.D. Pousa, J. Sidhu, N. Tilt, M. Lebwohl. Stable plasma concentration of certolizumab pegol is associated with persistent clinical improvement among patients with moderate to severe plaque psoriasis: Data from CIMPASI-1 and CIMPASI-2 25th World Congress of Dermatology Singapore 2023. 3-8 July 2023.
2. A. Morita, JF. Merola, LC. Coates, IB. McInnes, PJ. Mease, Y. Tanaka, P. Gisondi, AB. Gottlieb, B. Ink, D. Assudani, R. Bajracharya, J. Coarse, J. Eells, A. Asahina. Bimekizumab impact on joint and pain outcomes in patients with active psoriatic arthritis and psoriasis: Pooled 16-week results from two phase 3 randomised, placebo-controlled studies. 25th World Congress of Dermatology Singapore 2023. 3-8 July 2023.
3. Andreas Pinter, Matthias Augustin, David Pariser, Paolo Gisondi, Anna López-Ferrer, Matthias Hoffmann, Rhys Warham, Balint Szilagyi, Susanne Wiegatz, Valerie Ciaravino, Alice B. Gottlieb. Itching, skin pain and scaling in patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and Psoriasis Symptoms and Impacts Measure responses. 25th World Congress of Dermatology Singapore 2023. 3-8 July 2023.
4. Alice B. Gottlieb,¹ Paolo Gisondi,² Paul Sator,³ Jennifer Cather,⁴ Steven R. Feldman,⁵ Isabel Belinchón,⁶ Ronald Vender,⁷ Rhys Warham, Balint Szilagyi,¹⁰ Jérémy Lambert,¹¹ Matthias Augustin¹² Bimekizumab efficacy through 144 weeks in moderate to severe plaque psoriasis: Patient-reported outcomes from BE RADIANT. European Academy of Dermatology and Venereology - 32nd Congress. 11-15 October Berlin 2023
5. Kenneth B. Gordon,¹ Diamant Thaçi,² Melinda Gooderham,³ Yukari Okubo,⁴ Bruce Strober,⁵ Luke Peterson,⁶ Delphine Deherder,⁷ José M. López Pinto,⁸ Paolo Gisondi. Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in five phase 3/3b clinical trials. American Academy of Dermatology - 82nd Annual Meeting. 2024 AAD Annual Meeting March 8-12 in San Diego.
6. Bruce Strober; Linda Stein; Paolo Gisondi; Kate Orroth; Myriam Cordey; Shia Kent; Cynthia Deignan, Shauna Jardon; Rohini K. Hernandez; M. Alan Brookhart; April Armstrong. Waiting to Initiate Apremilast: Evidence of Disease Burden and Topical Cycling in Mild to Moderate Psoriasis in Real-World Clinical Practice. Maui Derm 2024.
7. Laure Gossec, Dafna D Gladman, Paolo Gisondi, Maarten de Wit, Alexis Ogdie, Barbara Ink, Vanessa Taieb, Jérémy Lambert, Laura C Coates. Bimekizumab treatment reduced disease impact in patients with psoriatic arthritis and psoriasis at baseline: up to 2-year results from two

phase 3 studies. *The 7th World Psoriasis & Psoriatic Arthritis Conference* 27-29 June 2024, Stockholm, Sweden.

8. Joseph F. Merola, Richard B. Warren, Diamant Thaçi, Kenneth B. Gordon, placeholder TBC, Bruce Strober, Curdin Conrad, Sarah Kavanaugh, José Manuel López Pinto, Bengt Hoepken, Paolo Gisondi. Bimekizumab simultaneous clearance of skin and nail psoriasis in patients with psoriasis: Assessing comparative efficacy in four phase 3/3b studies. *The 7th World Psoriasis & Psoriatic Arthritis Conference* 27-29 June 2024, Stockholm, Sweden.
9. Linda Stein Gold; Matthias Augustin, Howard Sofen; Paolo Gisondi; Shauna Jardon, PharmD; Jyotsna Reddy; Henry Zou; Kristina Callis Duffin. Efficacy of Apremilast in Adults With Mild-to-Moderate Plaque Psoriasis With Scalp Involvement: Pooled Data from PROMINENT, ADVANCE, and EMBRACE Trials. American Academy of Dermatology San Diego March 8-12, 2024.

CLINICAL TRIALS PARTICIPATED AS INVESTIGATOR

1. A randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of three dose levels of rosiglitazone maleate in the treatment of chronic plaque psoriasis (*Protocollo 49653/330*)
2. Studio multicentrico della durata di dodici settimane suddivise in una fase randomizzata, in doppio cieco, controllata verso placebo (veicolo), a gruppi paralleli, della durata di 6 settimane, seguita da un follow-up di 6 settimane in aperto, per valutare l'efficacia e la sicurezza di Elidel® crema 1% in pazienti con dermatite atopica del volto e del collo di grado lieve-moderato, intolleranti ai corticosteroidi topici (*Protocollo CASM981C2442*)
3. Clinical study of tacrolimus ointment over long-term – Control study - Adults (*Protocollo FG-506-06-40*)
4. A randomized, double-blind, double-dummy, multicenter, noninferiority phase III study to assess the safety and efficacy of topical 1% SB-275833 ointment, applied twice daily, versus oral cephalexin, 500 mg in adults, or 12.5 mg/kg (250 mg/5ml) in children, twice daily, in the treatment of secondarily-infected dermatoses
5. A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of infliximab induction therapy followed by multiple regimens of maintenance infliximab therapy in subjects with plaque-type psoriasis (*Protocollo EXPRESS II -CO168T44*)
6. A multicentre, open label phase IIIb/IV study of subcutaneously administered efalizumab in the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant of other systemic therapies including cyclosporine, methotrexate and PUVA.
7. An open label, randomized efficacy and safety study of infliximab versus methotrexate in the treatment of moderate to severe psoriasis (*Protocollo P04271*)
8. A randomised, double-blind, two period study to evaluate the safety and efficacy of etanercept on skin and joint disease in psoriasis subjects with psoriatic arthritis.
9. Protocollo compassionevole per l'uso di alefacept (AMEVIVE®) in pazienti affetti da psoriasi cronica in placche moderata-severa o severa per i quali le attuali terapie sistemiche non sono appropriate.
10. Protocollo per l'uso di etanercept (ENBREL®) in pazienti affetti da psoriasi cronica in placche severa per i quali le attuali terapie sistemiche non sono appropriate

11. Protocol UCB no. A00394: A Multicentre, Double-Blind, Two Parallel Groups, Randomized Trial over Four Weeks of Treatment to Compare the Clinical Efficacy and Safety of Levocetirizine 5 mg Oral Capsules Once Daily in the Morning vs. Desloratadine 5 mg Oral Capsules Once Daily in the Morning in Patients Suffering from Chronic Idiopathic Urticaria (CIU).
12. Protocol Schering Plough no. P05133: TANGO: Switching from Etanercept to Infliximab in the treatment of moderate to severe Psoriasis; A multicentre open label trial evaluating the efficacy, tolerance and safety.
13. Protocol Novartis no. CAEB071C2201: CAEB: A double blind, randomized, placebo controlled, multicentre, dose finding study of oral AEB071 assessing Psoriasis Area and Severity Index (PASI) response as a function of dose and treatment duration (primary outcome) in patients with plaque psoriasis.
14. Protocollo SCIDerm 055-006. Optimising outpatient care in mild to moderate psoriasis by a newly developed 'Topical Treatment Optimising Programme' - an international study using Daivobet®/Dovobet® Gel ('PSO-TOP').
15. MIUR – PRIN Malattie infiammatorie croniche della cute 2009-2011
16. A double blind, randomized, placebo controlled, multicenter, dose finding study of oral AEB071 assessing Psoriasis Area and Severity Index (PASI) response as a function of dose and treatment duration in patients with plaque psoriasis. (CAEB071C2201)
17. A randomized, double-blind, placebo-controlled trial of benzydamine hydrochloride cream in the treatment of plaque psoriasis: a proof-of-concept and dose-finding study. (030(H)SC09143)
18. An exploratory TRial to Assess Naturalistic Safety and efficacy outcomes In patients Transitioned to ustekinumab from previous methotrexate therapy (TRANSIT). (CNTO1275PSO4004)
19. Indagine multicentrica ed osservazionale sulle caratteristiche dei farmaci preferite dai pazienti per il trattamento della psoriasi: studio italiano con metodologia delle scelte discrete (PSORA) (CNTO1275PSO0001)
20. International Psoriasis Council – 2010. "Impact of Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an epidemiologic analysis"
21. A Randomized, Double Blind, Placebo controller, Parallel Groups, Pilot Study to Assess the Effects of Two New Nail Lacquers, Cyclosporine 5% And Calcipotriol 0.005%, In the Treatment of Nail Psoriasis (PM0812)

22. Pfizer – 2010. A Phase 3, Multi-site, Randomized, Mixed-Blind, Parallel-Group Treatment Withdrawl and Retreatment Study of the Efficacy and Safety of 2 Oral Doses of CP-690,550 In Subjects with Mocerate to Severe Chronic Plaque Psoriasis (A3921111)
23. Celgene – 2011. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis (ESTEEM2) (CC-10004-PSOR-009)
24. Leo Pharma - Ottimizzazione della terapia ambulatoriale nella psoriasi lieve e moderata per mezzo di un “Programma di Terapia Topica” di nuova concezione - studio internazionale con Dovobet® Gel (‘PSO-TOP’) ”.
25. Novartis CAIN457A2304 “SCULPTURE” 2011 - A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to severe chronic plaque-type psoriasis on either a fixed dose regimen or on a retreatment at start of relapse regimen
26. Novartis CAIN457A2304E1-A 2013 multicenter, double-blind and open label, 2 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate to severe chronic plaque-type psoriasis treated with either a fixed dose regimen or on a retreatment at start of relapse regimen
27. Novartis- CAIN457A2317 2014- A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with moderate to severe plaque psoriasis.

INVITED ORAL PRESENTATIONS IN CONGRESSES IN 2023

1. Il concetto di “disease modification” nella psoriasi. *Giornate Doriche di Dermatologia*. Ancona, 18-19 novembre 2023.
2. Tildrakizumab esperienze real life nel paziente con psoriasi. *Congresso Sidemast triregionale del nord est*. Mestre 17 dicembre 2023
3. Skin and nail evaluation. *Meeting GRAPPA* Milano 15-16 dicembre 2022.
4. Stato nell’arte della psoriasi. *XX giornate di Terapia in Dermatovenereologia* Catania 28-29 gennaio 2023.
5. La psoriasi tra 5 anni. *Time 2 Derm*. Roma 11-12 febbraio 2023.
6. Psoriasis symptoms. *Virtual IPC meeting*. 17 February 2023.
7. Early intervention in psoriasis management. *Twice the change*. Roma 22-23 febbraio 2023.
8. Il valore della farmacoeconomia in dermatite atopica. *DA talks*. Verona 4 marzo 2023.
9. JADE regimen. Il vantaggio dello stop and go. *Advance. Il futuro della dermatite atopica*. Roma 9-10 marzo 2023.
10. Place of apremilast in the therapy of psoriasis *Master course. Webinar*. March, 17, 2023.
11. The transition from PsO to PsA: the perspective of the dermatologist. *6th European Research and Development day*. Rome, March 30-31, 2023.
12. La fotoprotezione moderna: strategie di in ed out. *Solari e fotoprotezione: non solo raggi UV e SPF*. Trento 5 aprile 2023.
13. IL-23 in the real life. *Dermatologia clinica. Lombardo Veneta*. Lazise 13 14 aprile 2023.
14. Trattamento a lungo termine della psoriasi con secukinumab: evidenze della real life. *Dermatologia clinica. Lombardo Veneta*. Lazise 13 14 aprile 2023.
15. Virtual mini-stays. Webinar with the spanish group of psoriasis. April 26, 2023.
16. Presentazione clinica e diagnosi differenziale della GPP. *Top seminar 2023. GPP talks: dalla sfida della diagnosi a quella del trattamento*. Milano 27-28 aprile 2023.
17. Moderatore evento ECM "ASAP - As Soon As POSSible" Bologna 28-29 aprile 2023.
18. Fisiopatologia della psoriasi. *Personalizzazione della terapia in DA/PSO/HS : come andare verso una terapia di precisione* - Torino, 5 e 6 maggio 2023
19. Remission to target. Webinar 4 maggio 2023.
20. Disease modification in psoriasis. *Webinar Sidemast* 18 maggio 2023.
21. Il ruolo del dermatologo nella disease interception. *Congresso GISEA*. Modena 19 maggio 2023.
22. Psoriasi: una malattia sistemica. *PSO innovation*. Verona 20 maggio 2023

23. La artrite psoriasica dal punto di vista del dermatologo. *97^o Congresso Nazionale Sidemast*. Napoli 13-16 giugno 2023.
24. Inibizione duale IL-17A ed F: come colmare gli unmet need. *97^o Congresso Nazionale Sidemast*. Napoli 13-16 giugno 2023.
25. Psoriasi Pustolosa Generalizzata: il futuro cambia pelle. *97^o Congresso Nazionale Sidemast*. Napoli 13-16 giugno 2023.
26. IL-17, IL-12/23, IL-23 inhibitors in therapy of chronic plaque psoriasis. *IPC Latin America Masterclass*. June 22, 2023.
27. Fisiopatologia dell'acne. *Percorsi di cura e traguardi nel PATIENT JOURNEY DELL'ACNE*. Bologna, 23 giugno 2023.
28. Does non-severe psoriasis exist ? (workshop) *14th International Immunology Summit*. Prague 29 June- 1 July 2023.
29. FOCUS ON: Il ruolo dell'IL23 nell'Artrite Psoriasica. *PsA IN THE MIRROR Dermatologo e Reumatologo per la gestione della PsA. FAD Sincrona – Virtual Meeting ECM-* luglio, 5 settembre, 3 ottobre, 7 novembre, 5 dicembre 2023.
30. Clinica e terapia dell'acne. *Ducray Acne days*. Verona 14 settembre 2023.
31. Profilo di efficacia e sicurezza di abrocitinib nella dermatite atopica. *Seminari Dermatologici Italiani* 22 settembre 2023.
32. Disease modification in Psoriasis. *Sarajevo Dermatology days*. September 22-24, 2024.
33. The treatment of psoriasis in patients with cancer. *POZVÁNKA Satelitné symposium a Skin café EAST FOR SKIN 2023*. September 20, 2023.
34. Il metaverso della psoriasi pustolosa generalizzata. *60° Congresso Nazionale ADOI*. Vicenza 27-30 ottobre 2023.
35. Le linee guida della psoriasi volgare. *Certamen* 5-7 ottobre 2023 Roma.
36. Management of psoriasis in patients with a history of malignancy. *International Psoriasis Council. Philippine Psoriasis Symposium*. October 5, 2023
37. Management of cardiometabolic comorbidities in patients with psoriasis. *EADV Berlin* October 11-14, 2023.
38. Controversies in Dermatology. Therapeutic drug monitoring: no. *EADV Berlin* October 11-14, 2023.
39. La psoriasi una malattia della pelle che diventa sistemica: la prospettiva del dermatologo. *Terapia farmacologica e management del paziente psoriasico: update per il farmacista ospedaliero*. Roma 21 ottobre 2023.
40. Tavolo tecnico regionale sui biosimilari. Padova 24 ottobre 2023.

41. Disease modification in psoriasi. Seminari Dermatologici Italiani. 3 Novembre 2023.
42. Aspetti clinici epidemiologici della GPP. Webinar 21 novembre 2023.
43. Io e il mio prurito, Società Italiana di Dermatologia Allergologica Professionale e Ambientale
CONGRESSO NAZIONALE DA SI PA 20° NAPOLI 23-25 |11| 2023
44. How should we address the risk of arthritis in psoriasis? *Workshop GRAPPA@Milan Clinically relevant questions in psoriatic disease*. Milano 1 dicembre 2023.
45. Il ruolo dei JAK inibitori nella dermatite atopica e nella malattia psoriasica. *Congresso Regionale Triveneto 2023*. Mestre 16 dicembre 2023.
46. Disease modification in psoriasi. Il ruolo della IL-23 nella terapia della psoriasi. Webinar 22 dicembre 2023.

REVIEWER FOR THE FOLLOWING JOURNALS

British Journal of Dermatology

European Journal of Dermatology

Giornale Italiano di Dermatologia e Venereologia

Journal of the American Academy of Dermatology

Journal of the European Academy of Dermatology and Venereology

Pharmacological Research

Therapeutics and Clinical Risk Management

Journal of Rheumatology

Clinical and Experimental Dermatology

American Journal of Clinical Dermatology

Scandinavian Journal of Rheumatology

Biologics: targets and therapy

Dermatologic therapy

Nature reviews in rheumatology

Archives of Dermatological Research

Immunopharmacology and Immunotoxicology

Advances in psoriasis and inflammatory skin diseases

Journal of Investigative Dermatology

Dermatology Research and Practice

Open Journal of Dermatology

Obesity

Expert reviews in dermatology

EDITORIAL BOARD MEMBER

Editorial board member of the Journal of the European Academy of Dermatology and Venereology

Previous Associate Editor (section epidemiology) of the British Journal of Dermatology

Open Journal of Dermatology

Advances in psoriasis and inflammatory skin diseases

Revista Latinoamericana de Psoriasis y Artritis Psoriasica

Word Journal of Dermatology

Treatment strategies in Dermatology

World Journal of Translational Medicine

APMAR associazione persone con malattie reumatiche

Alternative & Integrative Medicine

Clinical Dermatology

METRIX

Citations **16668**

Index H **66**

Verona, 4 February 2024.



Prof. Paolo Gisondi
Department of Medicine
Section of Dermatology and Venereology
University of Verona
Piazzale A. Stefani 1
37126 Verona (Italy)
Tel +39-045-8122546
Fax +39-045-8027315
Email paolo.gisondi@univr.it